How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Nucleic Acid-based Drugs Market
- By Drug Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), MicroRNA (miRNA) Therapeutics, Aptamers, Ribozymes
- By Indication: Oncology, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders
- By Delivery Method: Lipid Nanoparticles (LNP), Viral Vectors, Conjugated Delivery Systems, Polymeric Nanoparticles, Exosomes
- By End User: Hospitals, Specialty Clinics, Research Institutes, Pharmaceutical Companies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antisense Oligonucleotides (ASOs) leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Nucleic Acid-based Drugs Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Drug Type 5
Indication 5
Delivery Method 5
End User 4
Companies profiled
Ionis Pharmaceuticals
Alnylam Pharmaceuticals
Sarepta Therapeutics
Dicerna Pharmaceuticals (a Novo Nordisk company)
BioNTech SE
Moderna Inc.
Arrowhead Pharmaceuticals
Akcea Therapeutics (a subsidiary of Ionis)
Wave Life Sciences
Duke University (not a company
but a key research entity)
Roche (through its subsidiary Genentech)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Ionis Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Alnylam Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sarepta Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Dicerna Pharmaceuticals (a Novo Nordisk company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BioNTech SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Arrowhead Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Akcea Therapeutics (a subsidiary of Ionis)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Wave Life Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Duke University (not a company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →but a key research entity)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Roche (through its subsidiary Genentech)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Pfizer Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Novartis AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Bristol-Myers Squibb
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Regulus Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,480M by 2033 · 10.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antisense Oligonucleotides (ASOs)51.8
- Small Interfering RNA (siRNA)16.3
- MicroRNA (miRNA) Therapeutics14.1
- Aptamers9.5
- Ribozymes8.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,728M → $4,061M · 11.3%
Europe$1,204M → $2,880M · 11.5%
Asia Pacific$1,099M → $2,574M · 11.2%
Latin America$680.6M → $1,507M · 10.5%
Middle East and Africa$523.5M → $1,107M · 9.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.262026
10.272027
10.282028
10.312029
10.312030
10.322031
10.342032
10.352033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Ionis Pharmaceuticals16.3
- Alnylam Pharmaceuticals16.1
- Sarepta Therapeutics12.3
- Dicerna Pharmaceuticals (a Novo Nordisk company)11.0
- BioNTech SE8.9
- Moderna Inc.7.3
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type31.2%
Indication19.8%
Delivery Method20.4%
End User28.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.5
- Europe23.7
- Asia Pacific21.2
- Latin America12.4
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | 77 | 84 | 77 | 83 | 96 | 74 | 82 |
| Alnylam Pharmaceuticals | 79 | 91 | 88 | 69 | 72 | 81 | 80 |
| Sarepta Therapeutics | 71 | 87 | 68 | 80 | 73 | 88 | 78 |
| Dicerna Pharmaceuticals (a Novo Nordisk company) | 73 | 79 | 60 | 72 | 81 | 71 | 73 |
| BioNTech SE | 54 | 58 | 65 | 72 | 58 | 69 | 63 |
| Moderna Inc. | 50 | 58 | 69 | 53 | 69 | 50 | 58 |
| Arrowhead Pharmaceuticals | 55 | 63 | 48 | 44 | 60 | 46 | 53 |
| Akcea Therapeutics (a subsidiary of Ionis) | 47 | 57 | 39 | 52 | 37 | 47 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Ionis Pharmaceuticals
- Alnylam Pharmaceuticals
- Sarepta Therapeutics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Alnylam Pharmaceuticals | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Sarepta Therapeutics | ✓ | ◐ | − | ✓ | ✓ | ✓ |
| Dicerna Pharmaceuticals (a Novo Nordisk company) | ◐ | ✓ | − | ◐ | ✓ | ✓ |
| BioNTech SE | ◐ | − | ✓ | ◐ | − | ◐ |
| Moderna Inc. | − | ◐ | ◐ | ◐ | − | − |
| Arrowhead Pharmaceuticals | − | ◐ | − | − | ◐ | − |
| Akcea Therapeutics (a subsidiary of Ionis) | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Ionis Pharmaceuticals82
2Alnylam Pharmaceuticals80
3Sarepta Therapeutics78
4Dicerna Pharmaceuticals (a Novo Nordisk company)73
5BioNTech SE63
6Moderna Inc.58
7Arrowhead Pharmaceuticals53
8Akcea Therapeutics (a subsidiary of Ionis)47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Ionis PharmaceuticalsAlnylam PharmaceuticalsSarepta Therapeutics
Challenger1
Strong scale, closing on the leaders.
Dicerna Pharmaceuticals (a Novo Nordisk company)
Contender2
Focused players with pockets of strength.
BioNTech SEModerna Inc.
Niche2
Specialists in a single segment or region.
Arrowhead PharmaceuticalsAkcea Therapeutics (a subsidiary of Ionis)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Nucleic Acid-based Drugs Market — a $771M beachhead inside a $10.9B market.
Beachhead (SOM)$771Mobtainable near-term
Serviceable (SAM)$4.57Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Antisense Oligonucleotides (ASOs)
Best fit — highest urgency & budget in Drug Type.
Economic buyer78 fit
Small Interfering RNA (siRNA)
Strong fit — clear ROI and a fast path to value.
End user66 fit
MicroRNA (miRNA) Therapeutics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Delivery Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel25%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Nucleic Acid-based Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified26%
Evaluation15%
Closed-won5%
$20.5KCAC
$76KLTV
3.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Nucleic Acid-based Drugs Market is a resilient opportunity — $4.37B by 2033, compounding at 3.6%.
TAM · 2025$3.31Btoday
TAM · 2033$4.37Bforecast
CAGR3.6%2027–2033
Cumulative$34.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.37BTotal addressable market
SAM$1.56BServiceable available market
SOM$279MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.6% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.37BLarge & growingTAM by 2033 at 3.6% CAGR
$1.56BServiceable nowreachable with today’s model
$279MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.41BBear2.3% CAGR
$4.37BBase3.6% CAGR
$5.60BBull4.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Nucleic Acid-based Drugs Market — a $2.30B market by 2033. Plan: grow share from 11.6% to 18.5%.
Market size · 2033$2.30Btotal addressable
Market CAGR3.5%2027–2033
Target share18.5%from 11.6% today
Revenue ambition$426Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.6% | 18.5% | On track |
| Revenue | $282M | $426M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 30.4% | 41.9% | At risk |
| Customer retention | 88.7% | 95.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $53M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Nucleic Acid-based Drugs Market conversation — a $3.88B market you can size, segment and defend in minutes.
Market size · 2033$3.88Btotal opportunity
Growth4.0%CAGR to 2033
Addressable buyers1,516+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 2 mopayback period
$60K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Ionis PharmaceuticalsAlnylam PharmaceuticalsSarepta TherapeuticsDicerna Pharmaceuticals (a Novo Nordisk company)BioNTech SEModerna Inc.Arrowhead PharmaceuticalsAkcea Therapeutics (a subsidiary of Ionis)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Nucleic Acid-based Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Nucleic Acid-based Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Nucleic Acid–Based Diagnostic Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportNucleic Acid Automatic Extraction System Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportNucleic Acid Amplification Detection and Diagnostics Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportNuclease Residue Detection Kit Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportNuclease Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportNuclear Radiopharmaceutical Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportNuclear Radiation Therapeutic Drugs Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportNuclear Pore Membrane Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportNuclear Pharmacy Market
Market size, share, segmentation and regional forecast.
$762M market · 2025 base year
View reportNuclear Molecular Imaging System Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportNuclear Medicine Therapy Market
Market size, share, segmentation and regional forecast.
$445M market · 2025 base year
View reportNuclear Medicine Solutions Market
Market size, share, segmentation and regional forecast.
$337M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.